RIDGE POLITICAL REVIEW
  • Home
  • Domestic
  • International
  • Opinions
  • Economics
  • Local
  • About
  • Contact
  • All Articles

All Articles

No Country for Trans Women: Persistent Shortages of Injectable Estrogen in the United States

1/21/2019

2 Comments

 
Picture

By Mason Krohn

For most of the FDA researchers at the Center for Biologics Evaluation and Research, May 3, 2017 was a somewhat uneventful day — except for those who kept their eyes peeled on the campus televisions. Alas, as a leaked email from the department reveals, the Trump administration instructed the department to lock every screen in the building on the Fox News channel. The lack of remotes and plethora of Laura Ingrahams yelling into the halls of the FDA may seem inconsequential, but, in truth, the gesture symbolizes the growing conservative tilt within health agencies under the Trump administration. As RPR contributor Injae Lee investigated,  within his first year in office, Trump banned words including “evidence-based”, “fetus”, and “transgender” from CDC reports. Furthermore, in surveys conducted by the Union of Concerned Scientists, 32 percent of FDA staff and 48 percent of CDC workers reported that the consideration of political interests at the agencies hinder science-based decision making. The Trump administration has even gone so far as to terminate federal recognition of trans identities by commanding the Department of Health and Human Services to alter the definition of gender under Title IX. In all cases, it appears that the federal government is chipping away at the research and study of LGBTQ+ issues through politicized attacks. However, these curtailments of governmental science are minor when compared to the slow and silent persecution of transgender communities perpetuated by the FDA, the healthcare system, and the pharmaceutical market in the form of injectable estrogen shortages.

For trans women, high doses of injectable estrogen are necessary to achieve desired feminine characteristics such as curvy hips, breasts, thinning face and hair growth. Though medical intervention is not necessary to be considered trans, a great amount of trans people opt for hormone therapy as a life-saving tool to alleviate their gender dysphoria. Researchers note that, for many patients, sex reassignment therapy (including hormone therapy) contributes to significant reductions in anxiety, depression, interpersonal sensitivity, hostility, and overall psychoneurotic distress. Any reduction in these symptoms is vital for members of the trans community in America, which faces a suicide rate 26 times the national average as reported by the largest survey of trans Americans to date. As renowned actress of Orange is the New Black, Laverne Cox, eloquently remarked, “Healthcare for trans women is a necessity. It is not elective. It is not cosmetic. It is life saving.”

Regardless of the evident cruciality of trans medical access, the path to hormone therapy is strenuous.Trans women seeking estrogen injections must first seek out a provider to write out a prescription. It seems like a simple task, but for trans women, this procedure is laden with barriers. First of all, 31 percent of transgender Americans lack regular access to health care. Discrepancies in access stem from stigma and ignorance from healthcare professionals; in fact, 22 percent of transgender people report avoiding doctors for fear of discrimination, which is of particular concern for sexual minorities in rural areas. Under the Church Amendments passed by Congress in the 1970s, medical practitioners in the United States reserve the right to reject any patients if the service contradicts their religion. Hence, even if trans women can overcome the fear of stigma, many doctors can turn them away out of hostility or sometimes out of pure lack of experience with trans patients. After all, in a Stanford University School of Medicine report, only 40 out of 132 U.S. and Canadian medical schools included content on gender transition in their curricula. Ultimately, stigma, inexperience, and legal discrimination have driven transgender patients away from medical spaces.

After jumping through the many hoops of trans primary care, severe shortages of injectable estrogen compound the difficulties of hormone therapy. Presently, a duopoly controls the market for injectable estrogen, leaving trans women with Delestrogen (a product of Par Pharmaceuticals) or Estradiol Valerate (a generic manufactured by Perrigo). A shortage of both substances commenced in July of 2016 and endured until June 12, 2017, but the only reasoning listed by the FDA was “shortage of an inactive ingredient component” for Estradiol Valerate and “other” for Delestrogen”. When the 2016 shortages took effect, Perrigo refused requests for comment by the Chicago Tribune, the Guardian, and Vice, offering no explanation for their withdrawal from the market. Par Pharmaceuticals, on the other hand, disclosed that when their supplier of Delestrogen’s main active ingredient pulled out, they had to alter their supply chain. By August 9, 2016 (within a month of the shortage commencing), Par representatives stated that thousands of Delestrogen vials were ready for sale. Nevertheless, Par had to await FDA approval of its new supplier before distributing the new Delestrogen. Therefore, the FDA is culpable for injectable estrogen shortages for over 10 months. It is understandable for the FDA to review the manufacturer for safety concerns, however, given the nature of the shortage, the FDA’s disregard for timeliness is more of an affront to the trans community than a sign of caution. Moreover, the FDA’s long winded scrutiny is suspicious given that there are 17 estrogen medications with approval from the FDA for cisgender menopausal women. Due to partial FDA incompetence and the lack of distributors in this field, trans women were left to suffer the consequences.

The question then arises: how did trans women who had been injecting high doses of estrogen last almost a year without any available supply? For some, the shortage entailed turning to the black market. Vendors on Deep Web marketplaces like Hansa and Valhalla link trans women to illicit producers largely based in India and the Philippines. Participating in these markets is dangerous, because hormones found there might be diluted or laced with harmful ingredients including but not limited to chalk and boric acid. Unfortunately, the only alternatives to the black market are estrogen pills or patches. Pills are less effective than injectable estrogen vials, come in lower doses than necessary, and pose the risk of blood clots. Patches are prohibitively expensive and are just as ineffectual as pills. At the end of the day, the shortage left trans women vulnerable and cut back on the progress many of them achieved with hormonal therapy.
    
Even though the combined shortage of Delestrogen and Estradiol Valerate concluded last year, the supply of injectable estrogen is still broadly sporadic and inaccessible. The cheaper generic, Estradiol Valerate, has repeatedly gone out of stock; in fact, the FDA currently lists the drug as “in shortage”. Hence, trans women’s only option is the name brand version, which is often outside of their budgetary restraints. Even then, Delestrogen tends to only be available in urban areas with steady demand, including New York, Los Angeles, and San Francisco. For Par Pharmaceuticals, there is little incentive to keep a supply in rural pharmacies, given that the trans community is only 0.6% of the US population and many trans Americans move to urban areas. Since Par faces little competition in the field, it can single-handedly decide the fate of trans citizens seeking hormone therapy by deciding price and distribution of the product.
  
So long as market barriers remain steep, no trans woman can count on the ready availability of the next prescription of estrogen. Without this access, issues of gender dysphoria and outrageously high suicide rates that are already alarming will proliferate in the trans community. Put simply, a quintessential treatment has been withheld from a disadvantaged group. It ultimately prompts the question: would trans women still face this reality if, instead of Fox News clamors, it was their painful stories that reverberated through the halls of the FDA?


​
2 Comments
Jim Pearson link
12/31/2019 07:40:26 am

Great read!!!
Estrogen and other hormones play a critical role in different types of physiological activities in the body.
However, the secretion of those hormones is influenced by many factors including the aging process.
An adequate amount of prescribed supplements should be provided to optimize the estrogen level in the body.

Reply
buy eriacta online link
1/18/2022 05:57:05 am

<a href="https://www.dosepharmacy.com/eriacta-100mg-tablet"> sildenafil 100 mg</a> It belongs to a group of medicines known as phosphodiesterase type 5 PDE 5 inhibitors. is used to treat erectile dysfunction in men. It works by increasing blood flow to the penis.

Reply



Leave a Reply.

    Archives

    December 2022
    November 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    March 2021
    February 2021
    January 2021
    November 2020
    October 2020
    September 2020
    July 2020
    June 2020
    May 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    September 2019
    June 2019
    May 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    June 2017
    May 2017
    December 2016
    November 2016
    June 2015
    May 2015
    January 2015
    November 2014
    February 2014
    December 2013
    August 2013
    May 2013
    March 2013
    November 2012
    September 2012
    April 2012
    March 2012
    February 2012
    January 2012
    November 2011
    October 2011
    September 2011
    June 2011

    Categories

    All
    Aadhavaarasan Raviarasan
    Adam Smith
    Albert Wu
    Alex Liao
    Alex Timoney
    Alicia Jen
    Alison Shim
    Andrea Lan
    Andrew Falduto
    Anvi Mahagaokar
    Atreya Misra
    Ayla D'Silva
    Bardia Vaseghi
    Benny Sun
    Bharat Sanka
    Brandon Lu
    Brian Wen
    Brinda Gurumoorthy
    Caitlin Schiffer
    Camille Shen
    Caroline Margiotta
    Caroline Sha
    Catherine Chen
    Cathy Chen
    Chloe Yang
    Christine Wang
    Daniel Pittaro
    Daniel Zhang
    Davis George
    Deeptanshu Singhvi
    Dilara Shahani
    Ellee Tomaru
    Emily Pan
    Emily Wang
    Erin Flaherty
    Felix Zheng
    Hitha Santosh
    Howard Wei
    Injae Lee
    Jacob Clott
    James Gao
    Jasmine Xie
    Jedson Boyle
    Jennifer Huang
    Joey Walter
    Jonathan Nemetz
    Jon Jen
    Julia Roos
    Kaitlin Smalling
    Katherine Wang
    Katie Kleinle
    Kevin Tang
    Kevin Yang
    Kishan Gandham
    Kunal Damaraju
    Kyanna Ouyang
    Logan Aviles
    Lucas Canteros-Paz
    Maggie Hsu
    Mariam Khan
    Mark Stachowski
    Mason Krohn
    Meghan Mangini
    Michael Shaw
    Mimi Petric
    Namita Kalghatgi
    Noah Smith
    Oliver Tang
    Omar Bekdash
    Pasha Saidi
    Priya Mullassaril
    Raheel Abubakar
    Ranen Miao
    Rayhan Murad
    Robert Johnson
    Ryan Walsh
    Saamia Khan
    Saloni Singhvi
    Sam Klein
    Sarah Ouyang
    Shaina Spector
    Shaurya Ganjoo
    Shiam Kannan
    Sunjay Melkote
    Tim O'Shea
    Tim Tang
    Vicki Liu
    Victoria Lu
    Vivek Gurumoorthy
    Wei Wen
    Willa Yu
    Zayna Kutty

rpr

About
Home
Read All
​
Contact

Sections

International
Domestic
Economics
​Opinions
Local
​
Search Site
© COPYRIGHT 2018 ALL RIGHTS RESERVED.
  • Home
  • Domestic
  • International
  • Opinions
  • Economics
  • Local
  • About
  • Contact
  • All Articles